Browse > Article

Safety Pharmacology of CJ-11555  

최재묵 (CJ 제약연구소)
이성학 (CJ 제약연구소)
김일환 (CJ 제약연구소)
박지은 (CJ 제약연구소)
김덕열 (CJ 제약연구소)
노현정 (CJ 제약연구소)
김택로 (CJ 제약연구소)
최광도 (CJ 제약연구소)
김영훈 (CJ 제약연구소)
Publication Information
Toxicological Research / v.20, no.2, 2004 , pp. 159-166 More about this Journal
Abstract
Safety pharmacological properties of CJ-11555, an anti-cirrhotic agent, were investigated in experimental animals and in vitro test system. CJ-11555 had no effects on normal body temperature in rats, motor coordination, chemoshock induced by pentetrazol, electric shock induced by electric shocker and writhing syndromes in mice at dose levels of 100, 300 and 1,000 mg/kg. CJ-11555 inhibited intestinal activity and prolonged hexobarbital-induced sleeping time in mice at the dose level of 1,000 mg/kg. CJ-11555 affected on general activity and behaviour tests in SD rats, such as lacrimation, ptosis, piloerection, decreased body tone, abnormal dispersion within the cage, diarrhoea, red colored faeces, slight hypothermia and decreased grooming, at the dose level of 1,000 mg/kg in rats. CJ-11555 was effected on cardiovascular and respiratory system in anesthetized beagle dogs, such as tachycardia, increase of mean blood pressure and decrease of PR interval, decrease of respiratory rate and minute volume, at dose levels of 10 and 30 mg/kg. However, these effects were also observed in vehicle treated anesthetized beagle dogs. In in vitro experiments, CJ-11555 inhibited agonists (histamine, acetyl-choline or $BaCl_2$) induced contraction of isolated guinea-pig at the concentration of 30$\times$$10^6$ M. CJ-11555 was weekly inhibited hERG channel current at concentrations of 10 and 30$\times$$10^6$ M, and $IC_{50}$ was estimated to be higher than 30${\times}$$10^6$M. Based on these results, it was concluded that CJ-11555 affected on cardiovascular and respiratory system, general activity and behaviour and hexobarbital-induced sleeping time at the dose level of 1,000 mg/kg and contraction of the smooth muscle and hERG channel current at the concentration of 30$\times$$10^6$ M.
Keywords
CJ-11555; Anti-cirrhotic agent; Safety pharmacology;
Citations & Related Records
연도 인용수 순위
  • Reference
1 의약품 등의 일반약리시험 지침 (식품의약품 안전청 고시 제1998-62호, 1998. 5. 29 개정)
2 ICH Harmonized Tripartite guideline (S7A) (2001): Safety pharmacology study for human pharmaceuticals
3 Kang, KW., Kim, Y.G., Cho, MK, Bae, S.K., Kim, C.w., Lee, M.G. and Kim, S.G. (2002b): Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding proteinmediated stellate cell inactivation. FASEB J., 16, 1988-1990
4 Irwin, S. (1968): Comprehensive observational assessment : A systemic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologica., 13, 222-257
5 Hamill, O.P., Marty, A., Neher, E., Sakmann, B. and Sigworth, F.J. (1981). Improve patch clamp techniques for high-resolution current recording from cells and cell-free membrane-patches. Pflgers Arch., 391, 85-100   DOI
6 Ansher, S. (1985): The chemotherapy of schistosomiasis. Ann Rev Pharmacol., 25, 485-508
7 Kang, K.W., Choi, S.H., Ha, J.R., Kim. C.W. and Kim, S.G. (2002a): Inhibition of dimethylnitrosamine-induced liver fibrosis by 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) in rats: suppression of transforming growth factorbeta1 and tumor necrosis factor-alpha expression. Chem. Biol. Interact., 139, 61-67.
8 Crowell, JA, Page, J.G., Rodman, L.E., Heath, J.E., Goldenthal, E.I., Hall, L.B. and Kelloff, G.J. (1997): Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1 ,2-dithiole-3thione, a potential chemopreventive agent. Fund Appl. Toxicol., 35, 9-21
9 Kensler, T.W., Egner, PA, Wang, J.B., Zhu, Y.R., Zhang, B.C., Qian, G.S., Kuang, S.Y., Gange, S.J., Jacobson, L.P., Munoz, A. and Groopman, J.D. (2002): Strategies for chemoprevention of liver cancer. Eur. J. Cancer. Prev., 2, 58-64